0001209191-21-042424.txt : 20210622
0001209191-21-042424.hdr.sgml : 20210622
20210622170050
ACCESSION NUMBER: 0001209191-21-042424
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210621
FILED AS OF DATE: 20210622
DATE AS OF CHANGE: 20210622
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Abel Robert Lorne
CENTRAL INDEX KEY: 0001798179
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39206
FILM NUMBER: 211036065
MAIL ADDRESS:
STREET 1: SCHRODINGER, INC.
STREET 2: 120 WEST 45TH STREET, 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Schrodinger, Inc.
CENTRAL INDEX KEY: 0001490978
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 954284541
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 120 WEST 45TH STREET
STREET 2: 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 503-299-1150
MAIL ADDRESS:
STREET 1: 120 WEST 45TH STREET
STREET 2: 17TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-21
0
0001490978
Schrodinger, Inc.
SDGR
0001798179
Abel Robert Lorne
C/O SCHRODINGER, INC.,
120 WEST 45TH STREET, 17TH FLOOR
NEW YORK
NY
10036
0
1
0
0
See Remarks
Common Stock
2021-06-21
4
M
0
7814
17.00
A
7814
D
Common Stock
2021-06-21
4
M
0
5574
4.34
A
13388
D
Common Stock
2021-06-21
4
M
0
2214
2.92
A
15602
D
Common Stock
2021-06-21
4
S
0
15602
74.1604
D
0
D
Stock Option (right to buy)
2.92
2021-06-21
4
M
0
2214
0.00
D
2027-06-01
Common Stock
2214
0
D
Stock Option (right to buy)
4.34
2021-06-21
4
M
0
5574
0.00
D
2028-11-29
Common Stock
5574
11148
D
Stock Option (right to buy)
17.00
2021-06-21
4
M
0
7814
0.00
D
2030-02-05
Common Stock
7814
125959
D
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 17, 2021.
The option was granted on June 1, 2017 and is fully vested.
This option was granted on November 29, 2018. The shares underlying the option vested with respect to 25% of the shares on December 31, 2019 and the remainder are scheduled to vest in equal monthly installments through December 31, 2022.
This option was granted on February 5, 2020. The shares underlying the option vested with respect to 25% of the shares on February 5, 2021 and the remainder are scheduled to vest in equal monthly installments through February 5, 2024.
EVP, Chief Computational Scientist, Head of Modeling R&D
/s/ Donald Shum, as attorney-in-fact for Robert Lorne Abel
2021-06-22